Weight Loss Regimen

Abstract

Obesity and/or diabetes are treated by partially inhibiting circulating leptin in a person in need thereof.

What is claimed is: 
     
         1 . A method of treating obesity or diabetes comprising partially inhibiting circulating leptin by 30-90% in a person in need thereof. 
     
     
         2 . The method of  claim 1  wherein the partial inhibition is 40-80%. 
     
     
         3 . The method of  claim 1  wherein the partial inhibition is 50-70%. 
     
     
         4 . The method of  claim 1  wherein the inhibiting step is performed under thermoneutral conditions for the person. 
     
     
         5 . The method of  claim 2  wherein the inhibiting step is performed under thermoneutral conditions for the person. 
     
     
         6 . The method of  claim 1  wherein the inhibiting step comprises administering to the person a therapeutic leptin neutralizing antibody. 
     
     
         7 . The method of  claim 5  wherein the inhibiting step comprises administering to the person a therapeutic leptin neutralizing antibody. 
     
     
         8 . The method of  claim 1  wherein the inhibiting step comprises administering to the person a therapeutic leptin neutralizing antibody, wherein the antibody neutralizes by reducing engagement of leptin receptor and subsequent signaling of the receptor as assessed by STAT activation, wherein circulating leptin is reduced. 
     
     
         9 . The method of  claim 1  wherein the inhibiting step comprises administering to the person a therapeutic leptin antagonist that is a leptin mutein. 
     
     
         10 . The method of  claim 5  wherein the inhibiting step comprises administering to the person a therapeutic leptin antagonist that is a leptin mutein. 
     
     
         11 . The method of  claim 1  wherein the inhibiting step comprises administering to the person a therapeutic leptin neutralizing antisense oligonucleotide (ASO), small interfering RNA (siRNAs) or short hairpin RNA (shRNA). 
     
     
         12 . The method of  claim 5  wherein the inhibiting step comprises administering to the person a therapeutic leptin neutralizing antisense oligonucleotide (ASO), small interfering RNA (siRNAs) or short hairpin RNA (shRNA). 
     
     
         13 . The method of  claim 1  wherein the inhibiting step comprises knocking down of leptin expression using CRISPR/Cas9 or CRE/loxP. 
     
     
         14 . The method of  claim 5  wherein the inhibiting step comprises knocking down of leptin expression using CRISPR/Cas9 or CRE/loxP. 
     
     
         15 . The method of  claim 1  further comprising detecting a resultant improvement in the obesity or diabetes in the person. 
     
     
         16 . The method of  claim 5  further comprising detecting a resultant improvement in the obesity or diabetes in the person. 
     
     
         17 . The method of  claim 1  further comprising detecting the resultant partial inhibition of circulating leptin in the person. 
     
     
         18 . The method of  claim 5  further comprising detecting the resultant partial inhibition of circulating leptin in the person. 
     
     
         19 . The method of  claim 1  further comprising titrating down the levels of leptin of the person to effect leptin sensitization without effecting weight gain. 
     
     
         20 . The method of  claim 5  further comprising titrating down the levels of leptin of the person to effect leptin sensitization without effecting weight gain.